IQVIA Holdings Inc. (NYSE:IQV) Stake Lowered by Securian Asset Management Inc.

Securian Asset Management Inc. trimmed its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,255 shares of the medical research company’s stock after selling 323 shares during the period. Securian Asset Management Inc.’s holdings in IQVIA were worth $1,819,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of IQV. Smith Group Asset Management LLC purchased a new stake in shares of IQVIA during the 4th quarter worth about $1,616,000. Simplify Asset Management Inc. raised its position in IQVIA by 67.8% during the third quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock valued at $2,284,000 after acquiring an additional 3,894 shares in the last quarter. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Hickory Asset Management Inc. bought a new stake in IQVIA in the fourth quarter worth approximately $941,000. Finally, Fifth Third Bancorp increased its stake in shares of IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of IQVIA stock opened at $181.53 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm’s 50-day simple moving average is $196.87 and its 200-day simple moving average is $211.38. The firm has a market cap of $32.01 billion, a P/E ratio of 24.20, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.76.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research note on Tuesday, February 18th. Stephens assumed coverage on IQVIA in a research note on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Robert W. Baird cut their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Stifel Nicolaus decreased their target price on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Truist Financial reissued a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.